Article Text

PDF
CP-155 Use and safety profile of oral medication before secondline in relapsing-remitting multiple sclerosis
  1. M Dominguez Cantero,
  2. LC Fernandez Lison,
  3. S Araniz Diez,
  4. P Perez Puente,
  5. MR Garrido Ameigeira,
  6. L Martin Rizo,
  7. M Malpartida Flores,
  8. MT Salas Rivera,
  9. M Gomez Espárrago,
  10. MT Martin Cillero
  1. Complejo Hospitalario de Cáceres, Hospital Pharmacy, Cáceres, Spain

Abstract

Background Multiple sclerosis is a chronic demyelinating CNS disease. Oral drugs have recently been approved for relapsing-remitting multiple sclerosis (RRMS).

Purpose To analyse the use and safety profile of dimethylfumarate (DMF) and teriflunomide (TRF) in RRMS.

Material and methods A descriptive retrospective observational study of patients treated with DMF or TRF from January to 15 October 2015.

Variables: average age, sex, previous treatment, reason for changing treatment to oral treatment and average duration of treatment with DMF/TRF. In patients with previous therapies, the reason for switching was stratified as: (a) safety, caused by adverse effects (AE) to interferon beta (IFNβ)/glatiramer acetate (GA); and (b) efficacy, relapse within 6 months prior to the beginning of DMF/TRF. Analysis of the safety profile: percentage of patients with one or more AE associated with DMF/TRF.

Results 27 (18.1%) patients of 149 treated for MS in our outpatients pharmaceutical care unit initiated oral medication. 9 were excluded for lack of safety data. Overall, 4 patients had no prior treatment, and the rest had received the following: 41.1% IFNβ-1a, 21% IFNβ-1b and GA 15.8%. The switch to TRF/DMF occurred in 63% for safety reasons.

61.1% (11/18) started treatment with TRF, 40.7 ± 8.9 years, 85.7% women. 3 patients had no previous treatment, and in the remaining 38.5% had received IFNβ-1a, 27.3% IFNβ-1b and 18.2% GA. Switching to TRF for safety reasons occurred in 90.9%. Duration of treatment was 23.5 ± 9.2 weeks with TRF. 36.4% (4/11) of patients had an AE, the most frequent being diarrhoea (27.3%).

7 patients began with DMF, 34.3 ± 9.8 years, 75% women. 2 patients had not been treated previously and the rest had been treated with: 42.9% IFNβ-1a, 14.3% IFNβ-1b and 14.3% GA. 66.7% of the changes in DMF were for safety reasons. Average duration of treatment was 23.8 ± 2.7 weeks. 57.1% (4/7) had an AE, the most common being gastrointestinal disorders (57.1%); 2 patients required dose reduction.

Conclusion A high percentage of patients had received prior parenteral treatment. In fact, adverse reactions were the most frequent reason for changing to TRF/DMF.

According to our study, patients who began treatment with oral TRF had a slightly better safety profile compared with patients who started with DMF.

References and/or Acknowledgements Thanks to Julia Becerra Ramirez for the translation of the abstract.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.